WINGNAY CHERNESKY: Open Payments
NPI 1437830619 · CATONSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,469 in 98 payments from 22 companies in 2025. Trend: 2023 $697 · 2024 $1,495 · 2025 $2,469
Food & beverage: $2,385Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $348 |
| Madrigal Pharmaceuticals | 9 | $337 |
| GENZYME CORPORATION | 8 | $301 |
| Ardelyx, Inc. | 13 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $264 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $146 |
| ABBVIE INC. | 6 | $120 |
| Aimmune Therapeutics, Inc. | 4 | $110 |
| PFIZER INC. | 6 | $101 |
| Lilly USA, LLC | 3 | $89 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, IBSRELA, ENTYVIO, XIFAXAN, VOWST, OMVOH.
Industry payments across MD — which companies pay providers there.
